Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: A double‐blind, randomized, placebo‐controlled trial. Issue 6 (30th April 2014)

• Record Type: Journal Article
• Authors: Riss, Dominik; Burian, Martin; Wolf, Axel; Kranebitter, Veronika; Kaider, Alexandra; Arnoldner, Christoph
• Is Part Of: Head & neck. Volume 37:Issue 6(2015:Jun.)
• Page Start: 783
• Page End: 787
• Publication Date: 2014-04-30
• Subjects: Head -- Diseases -- Periodicals; Neck -- Diseases -- Periodicals; Head -- Periodicals; Neck -- Periodicals; Face -- Periodicals; 617.51059
• DOI: 10.1002/hed.23655
• Languages: English
• ISSNs: 1043-3074

Abstract

<abstract abstract-type="main"> <title>Abstract</title> <sec id="hed23655-sec-0001" sec-type="section"> <title>Background</title> <p>The purpose of this study was to investigate the efficacy of bevacizumab ("Avastin") for the treatment of epistaxis in hereditary hemorrhagic telangiectasia (HHT).</p> </sec> <sec id="hed23655-sec-0002" sec-type="section"> <title>Methods</title> <p>In this double blind, placebo controlled trial, 15 adult patients with HHT with a minimum of 2 epistaxis episodes per week were randomized. A history of thromboembolic events or recent or planned surgery led to exclusion. Patients received a single intranasal submucosal injection (10 mL) of 100 mg bevacizumab or placebo. The primary outcome was the relative reduction of average daily epistaxis visual analog score (VAS).</p> </sec> <sec id="hed23655-sec-0003" sec-type="section"> <title>Results</title> <p>Average daily posttreatment VAS scores decreased by 27% in the bevacizumab group and by 3% in the placebo group (<italic>p</italic> = .57). The reduction in HHT epistaxis severity scores was ‐0.61 greater in the bevacizumab group compared to the placebo group (<italic>p</italic> = .34).</p> </sec> <sec id="hed23655-sec-0004" sec-type="section"> <title>Conclusion</title> <p>Results show a trend toward reduced epistaxis with bevacizumab. This further supports the use of bevacizumab in HHT. Clincial Trials. gov number: NCT01314274 © 2014 Wiley Periodicals, Inc. <italic>Head Neck</italic> 37: 783–787, 2015</p> </sec> </abstract>